Csl
CSL Limited, commonly referred to as CSL, is a global biotechnology leader headquartered in Australia. Founded in 1916, the company has evolved significantly, establishing a strong presence in key operational regions including North America, Europe, and Asia-Pacific. Specialising in the development of innovative therapies for rare and serious diseases, CSL focuses on areas such as immunology, haematology, and respiratory health. The company is renowned for its core products, including immunoglobulins and clotting factors, which are distinguished by their high quality and efficacy. CSL's commitment to research and development has positioned it as a market leader, with notable achievements such as being consistently ranked among the top biopharmaceutical companies globally. With a rich history and a dedication to improving patient outcomes, CSL continues to set benchmarks in the biotechnology industry.
DitchCarbon Score
How does Csl's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Csl's score of 29 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Csl's reported carbon emissions
In 2023, CSL Limited reported total carbon emissions of approximately 336,000,000 kg CO2e, comprising 113,000,000 kg CO2e from Scope 1 and 223,000,000 kg CO2e from Scope 2 emissions. This marks a reduction from 347,000,000 kg CO2e in 2022, indicating a commitment to lowering their carbon footprint. CSL has disclosed emissions data for Scope 1, 2, and 3, with Scope 3 emissions reaching about 2,284,000,000 kg CO2e in 2021 and remaining consistent in subsequent years. The company has set near-term reduction targets, although it has not committed to a net-zero target as of now. CSL's emissions intensity has improved, with a reported Scope 1 and 2 GHG intensity of approximately 0.0252 kg CO2e per USD of revenue in 2023. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector and is headquartered in Australia. Overall, CSL's ongoing efforts reflect a proactive approach to climate commitments, focusing on reducing emissions while maintaining operational growth.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Csl is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
